Leerink analyst Seamus Fernandez says he is more comfortable with the differentiated safety profile and tolerability of Intra-Cellular's (ITCI) ITI-007 ahead of the second Phase 3 schizophrenia study readout, after meeting with the company's management. Fernandez believes ITI-007 would make an "excellent" addition to Johnson & Johnson's (JNJ) or Pfizer's (PFE) aging CNS portfolio. The analyst noted that Intra-Cellular has sufficient capital to complete the Phase 3 program in schizophrenia and bipolar depression while funding a Phase 2 study in behavioral disturbances of dementia. Fernandez reiterates an Outperform rating and $95 price target on Intra-Cellular's shares.

Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.